Aktuellt
SENASTE
Ahead of the Q3 report, we look for 42% y/y sales growth. In our view, SyntheticMR remains well-positioned for continued growth and we see a multitude of potential growth levers for the years ahead. Ahead of Q3, we lower our 2021 estimates marginally while increasing our 2022-23 estimates to reflect the recently expanded agreements with Philips and Siemens. Our new DCF-based fair value range is SEK 43-56 (previously SEK 38-50).
LÄS MER
